Ab­b­vie, Prin­cip­ia join forces on im­muno­pro­tea­some in­hibitors; Scripps de­vel­ops hero­in vac­cine, FDA fast tracks NGF pain drug

→  Ab­b­vie and Prin­cip­ia are col­lab­o­rat­ing to de­vel­op oral im­muno­pro­tea­some in­hibitors to treat au­toim­mune dis­ease us­ing nov­el tech­nol­o­gy dis­cov­ered at Prin­cip­ia. Fi­nan­cial terms were not dis­closed, but the two will work to­geth­er dur­ing de­vel­op­ment and pre­clin­i­cal test­ing. Then Ab­b­vie will move the tech­nol­o­gy for­ward to the clin­i­cal phase.

→  Sci­en­tists at the Scripps Re­search In­sti­tute have de­vel­oped a vac­cine against an un­usu­al tar­get – hero­in. The re­searchers gave their vac­cine to rhe­sus mon­keys and showed that it pre­vent­ed them from ex­pe­ri­enc­ing a high when ex­posed to the drug months lat­er. The re­searchers will be­gin test­ing the vac­cine, which they be­lieve will help ad­dicts avoid re­laps­ing. The vac­cine does not work for oth­er opi­oids, nor does it pre­vent over­dos­es.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN